drugset / Trial / NCT05745233
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
NaSingle-groupOpen-labelTreatment
Summary
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary tract cancers.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2026-12
- Completion
- 2026-12
Publications
- Background Wang ST, Chiu CF, Bai HJ, Bai LY. Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites. Eur J Cancer. 2021 May;148:48-50. doi: 10.1016/j.ejca.2021.01.045. Epub 2021 Mar 15. No abstract available.
- Wang HT, Yu YL, Lo WJ, Lin MC, Chu CL, Chen CY, Wang ST, Chiu CF, Bai EJ, Bai LY. Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer. Int J Clin Oncol. 2026 Feb;31(2):281-291. doi: 10.1007/s10147-025-02930-y. Epub 2025 Dec 10.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 20 mg | Other |
| Subject | Pembrolizumab | Monoclonal antibody | 20 mg | Other |